Institution
Geelong Hospital
Healthcare•Geelong, Victoria, Australia•
About: Geelong Hospital is a healthcare organization based out in Geelong, Victoria, Australia. It is known for research contribution in the topics: Population & Percutaneous coronary intervention. The organization has 595 authors who have published 729 publications receiving 27056 citations. The organization is also known as: University Hospital Geelong.
Topics: Population, Percutaneous coronary intervention, Myocardial infarction, Health care, Intensive care
Papers published on a yearly basis
Papers
More filters
••
McGill University1, Ludwig Maximilian University of Munich2, The Royal Marsden NHS Foundation Trust3, Autonomous University of Barcelona4, Geelong Hospital5, University of Marburg6, University of Edinburgh7, Pontifícia Universidade Católica do Rio Grande do Sul8, National Taiwan University9, University of Copenhagen10, Tel Aviv Sourasky Medical Center11, Russian Academy12, University of Düsseldorf13, University of Hamburg14, University of British Columbia15, University of Bern16, Hoffmann-La Roche17, Université libre de Bruxelles18, Harvard University19
TL;DR: One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.
Abstract: background Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy. methods This international, multicenter, randomized trial compared one or two years of trastuzumab given every three weeks with observation in patients with HER2-positive and either node-negative or node-positive breast cancer who had completed locoregional therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy. results Data were available for 1694 women randomly assigned to two years of treatment with trastuzumab, 1694 women assigned to one year of trastuzumab, and 1693 women assigned to observation. We report here the results only of treatment with trastuzumab for one year or observation. At the first planned interim analysis (median follow-up of one year), 347 events (recurrence of breast cancer, contralateral breast cancer, second nonbreast malignant disease, or death) were observed: 127 events in the trastuzumab group and 220 in the observation group. The unadjusted hazard ratio for an event in the trastuzumab group, as compared with the observation group, was 0.54 (95 percent confidence interval, 0.43 to 0.67; P<0.0001 by the log-rank test, crossing the interim analysis boundary), representing an absolute benefit in terms of disease-free survival at two years of 8.4 percentage points. Overall survival in the two groups was not significantly different (29 deaths with trastuzumab vs. 37 with observation). Severe cardiotoxicity developed in 0.5 percent of the women who were treated with trastuzumab. conclusions One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer. (clinicaltrials.gov number, NCT 00045032.)
4,815 citations
••
The Royal Marsden NHS Foundation Trust1, Harvard University2, Université libre de Bruxelles3, Hoffmann-La Roche4, European Institute of Oncology5, Ludwig Maximilian University of Munich6, Hebron University7, Western General Hospital8, Geelong Hospital9, Karolinska Institutet10, Weston Park Hospital11, Westmead Hospital12
TL;DR: The results show that 1 year of treatment with trastuzumab after adjuvant chemotherapy has a significant overall survival benefit after a median follow-up of 2 years, and the emergence of this benefit after only 2 years reinforces the importance of trastizumab in the treatment of women with HER2-positive early breast cancer.
1,489 citations
••
Duke University1, University of Barcelona2, Drexel University3, Tel Aviv University4, Alfred Hospital5, University of Michigan6, University of Zagreb7, Medical University of South Carolina8, Federal University of Rio de Janeiro9, Autonomous University of Barcelona10, Geelong Hospital11, University of Amsterdam12, Wayne State University13, University of California, Los Angeles14
TL;DR: Characteristics of patients with S aureus IE vary significantly by region, and further studies are required to determine the causes of regional variation.
Abstract: ContextThe global significance of infective endocarditis (IE) caused by Staphylococcus aureus is unknown.ObjectivesTo document the international emergence of health care–associated S aureus IE and methicillin-resistant S aureus (MRSA) IE and to evaluate regional variation in patients with S aureus IE.Design, Setting, and ParticipantsProspective observational cohort study set in 39 medical centers in
16 countries. Participants were a population of 1779 patients with definite
IE as defined by Duke criteria who were enrolled in the International Collaboration
on Endocarditis-Prospective Cohort Study from June 2000 to December 2003.Main Outcome MeasureIn-hospital mortality.ResultsS aureus was the most common pathogen among
the 1779 cases of definite IE in the International Collaboration on Endocarditis
Prospective-Cohort Study (558 patients, 31.4%). Health care−associated
infection was the most common form of S aureus IE
(218 patients, 39.1%), accounting for 25.9% (Australia/New Zealand) to 54.2%
(Brazil) of cases. Most patients with health care−associated S aureus IE (131 patients, 60.1%) acquired the infection outside of
the hospital. MRSA IE was more common in the United States (37.2%) and Brazil
(37.5%) than in Europe/Middle East (23.7%) and Australia/New Zealand (15.5%, P<.001). Persistent bacteremia was independently associated
with MRSA IE (odds ratio, 6.2; 95% confidence interval, 2.9-13.2). Patients
in the United States were most likely to be hemodialysis dependent, to have
diabetes, to have a presumed intravascular device source, to receive vancomycin,
to be infected with MRSA, and to have persistent bacteremia (P<.001 for all comparisons).ConclusionsS aureus is the leading cause of IE in many
regions of the world. Characteristics of patients with S aureus IE vary significantly by region. Further studies are required
to determine the causes of regional variation.
1,101 citations
••
National and Kapodistrian University of Athens1, Harvard University2, Université libre de Bruxelles3, Hoffmann-La Roche4, European Institute of Oncology5, The Royal Marsden NHS Foundation Trust6, Western General Hospital7, University of São Paulo8, Fudan University9, University of Toronto10, Geelong Hospital11
TL;DR: Treatment with adjuvant trastuzumab for 1 year after chemotherapy is associated with significant clinical benefit at 4-year median follow-up and a substantial selective crossover of patients in the observation group to trastzumab was associated with improved outcomes for this cohort.
Abstract: Summary Background Treatment with adjuvant trastuzumab for 1 year improves disease-free survival and overall survival in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We aimed to assess disease-free survival and overall survival after a median follow-up of 4 years for patients enrolled on the Herceptin Adjuvant (HERA) trial. Methods The HERA trial is an international, multicentre, randomised, open-label, phase 3 trial comparing treatment with trastuzumab for 1 and 2 years with observation after standard neoadjuvant, adjuvant chemotherapy, or both in patients with HER2-positive early breast cancer. The primary endpoint was disease-free survival. After a positive first interim analysis at a median follow-up of 1 year for the comparison of treatment with trastuzumab for 1 year with observation, event-free patients in the observation group were allowed to cross over to receive trastuzumab. We report trial outcomes for the 1-year trastuzumab and observation groups at a median follow-up of 48·4 months (IQR 42·0–56·5) and assess the effect of the extensive crossover to trastuzumab. Our analysis was by intention-to-treat. The HERA trial is registered with the European Clinical Trials Database, number 2005-002385-11. Findings The HERA trial population comprised 1698 patients randomly assigned to the observation group and 1703 to the 1-year trastuzumab group. Intention-to-treat analysis of disease-free survival showed a significant benefit in favour of patients in the 1-year trastuzumab group (4-year disease-free survival 78·6%) compared with the observation group (4-year disease-free survival 72·2%; hazard ratio [HR] 0·76; 95% CI 0·66–0·87; p vs 87·7%, respectively; HR 0·85; 95% CI 0·70–1·04; p=0·11). Overall, 885 patients (52%) of the 1698 patients in the observation group crossed over to receive trastuzumab, and began treatment at median 22·8 months (range 4·5–52·7) from randomisation. In a non-randomised comparison, patients in the selective-crossover cohort had fewer disease-free survival events than patients remaining in the observation group (adjusted HR 0·68; 95% CI 0·51–0·90; p=0·0077). Higher incidences of grade 3–4 and fatal adverse events were noted on 1-year trastuzumab than in the observation group. The most common grade 3 or 4 adverse events, each in less than 1% of patients, were congestive cardiac failure, hypertension, arthralgia, back pain, central-line infection, hot flush, headache, and diarrhoea. Interpretation Treatment with adjuvant trastuzumab for 1 year after chemotherapy is associated with significant clinical benefit at 4-year median follow-up. The substantial selective crossover of patients in the observation group to trastuzumab was associated with improved outcomes for this cohort. Funding F Hoffmann-La Roche, Michelangelo Foundation.
587 citations
••
Walter and Eliza Hall Institute of Medical Research1, Millennium Institute2, Griffith University3, University of Queensland4, University of Oxford5, University of Tasmania6, Royal Melbourne Hospital7, University of Melbourne8, John Hunter Hospital9, University of Newcastle10, Nepean Hospital11, University of Otago12, University of Auckland13, Box Hill Hospital14, Sir Charles Gairdner Hospital15, Geelong Hospital16, Royal Brisbane and Women's Hospital17, Flinders University18, University College Dublin19
TL;DR: To identify multiple sclerosis (MS) susceptibility loci, a genome-wide association study in 1,618 cases and used shared data for 3,413 controls and observed a statistical interaction between SNPs in EVI5-RPL5 and HLA-DR15.
Abstract: To identify multiple sclerosis (MS) susceptibility loci, we conducted a genome-wide association study (GWAS) in 1,618 cases and used shared data for 3,413 controls. We performed replication in an independent set of 2,256 cases and 2,310 controls, for a total of 3,874 cases and 5,723 controls. We identified risk-associated SNPs on chromosome 12q13-14 (rs703842, P = 5.4 x 10(-11); rs10876994, P = 2.7 x 10(-10); rs12368653, P = 1.0 x 10(-7)) and upstream of CD40 on chromosome 20q13 (rs6074022, P = 1.3 x 10(-7); rs1569723, P = 2.9 x 10(-7)). Both loci are also associated with other autoimmune diseases. We also replicated several known MS associations (HLA-DR15, P = 7.0 x 10(-184); CD58, P = 9.6 x 10(-8); EVI5-RPL5, P = 2.5 x 10(-6); IL2RA, P = 7.4 x 10(-6); CLEC16A, P = 1.1 x 10(-4); IL7R, P = 1.3 x 10(-3); TYK2, P = 3.5 x 10(-3)) and observed a statistical interaction between SNPs in EVI5-RPL5 and HLA-DR15 (P = 0.001).
497 citations
Authors
Showing all 595 results
Name | H-index | Papers | Citations |
---|---|---|---|
Rinaldo Bellomo | 147 | 1714 | 120052 |
Michael Bailey | 95 | 617 | 34692 |
John J McNeil | 82 | 592 | 30524 |
David H. Walker | 79 | 526 | 25214 |
Peter Cameron | 78 | 773 | 29109 |
Geoffrey C. Nicholson | 70 | 262 | 15197 |
Julie A. Pasco | 70 | 413 | 16295 |
Allen C. Cheng | 69 | 498 | 19931 |
Vsevolod L. Popov | 64 | 258 | 12053 |
Mark A. Kotowicz | 60 | 271 | 12768 |
Ravinder Reddy | 57 | 249 | 11091 |
David M. Ashley | 49 | 210 | 9436 |
Nigel Spry | 49 | 195 | 8542 |
Shaun P. Brennecke | 47 | 310 | 8783 |
Margaret J. Henry | 45 | 124 | 6396 |